Holen Sie sich die Stockscreener-App
2.095
0.38%
-0.015
Inflarx Nv Aktie (IFRX) Neueste Nachrichten
Price to book forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos - TipRanks
InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan
InflaRx to explore regulatory path for AAV drugs in Europe - Investing.com
InflaRx to explore regulatory path for AAV drugs in Europe By Investing.com - Investing.com Canada
EMA move on Tavneos pushes InflaRx to widen AAV plan in Europe - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Price to sales forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBITDA forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Price to earnings forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to sales forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to book forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Enterprise value to revenue forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBIT forward of InflaRx N.V. – GETTEX:IF0 - TradingView
ETFs Investing in InflaRx N.V. Stocks - TradingView
InflaRx N.V. Actuals & Estimates (HAM:IF0) - TradingView
InflaRx N.V. Actuals & Estimates (GETTEX:IF0) - TradingView
IFRX Forecast — Price Target — Prediction for 2027 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InflaRx StockAnalyst views and trading setup midweek - AD HOC NEWS
InflaRx NV (IFRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IFRX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline, Though Stock DeclinesStrong Earnings Momentum - newsline.com
InflaRx N.V. Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEarnings Growth Forecast - newsline.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock SlipsPost-Announcement Reaction - newsline.com
What Do Analysts Say About InflaRx N.V. (IFRX)? - Insider Monkey
InflaRx N.V. (IFRX) Q1 2026 Earnings: EPS Exceeds Expectations as Drug Development Advances - newsline.com
IFRX Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclinePre-Earnings Drift - newsline.com
InflaRx prices $150 million share offering at $2 per share - Investing.com
InflaRx to develop izicopan for kidney disease treatment - Investing.com
InflaRx prices $150 million share offering at $2 per share By Investing.com - Investing.com Australia
INFLARX NV (IFRX) Stock Chart - ChartMill
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update - AD HOC NEWS
Wall Street Firms Upgrade InflaRx Following Strategic Kidney Disease Focus - HarianBasis.co
Raymond James Upgrades InflaRx Following Clinical Shift - asatunews.co.id
InflaRx N.V. (IFRX) Edges Higher with Modest Gains, Tests Key Resistance ZoneHigh Volume Stocks - The Legal Advocate
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now - Yahoo Finance
5 Most Volatile Penny Stocks to Buy Now - Insider Monkey
InflaRx N.V. Shows Resilience: IFRX Stock Edges Higher on Modest VolumePassive Flow - newsline.com
InflaRx N.V. (IFRX) Tumbles 7% as Shares Test Key Support LevelsSmart Beta Flow - newsline.com
InflaRx (IFRX) Surges Nearly 5%, Testing Key Resistance at $2.88Last Point Support - thelegaladvocate.com
IFRXInflaRx NV Stock Price and Quote - Finviz
InflaRx (IFRX) Q4 2025 Earnings: Slight EPS Beat Amid Pre‑Revenue PhaseStrong Earnings Momentum - The Legal Advocate
InflaRx N.V. (IFRX) Q4 2025 Earnings: Narrower Loss and Pipeline Progress Lift Sentiment - thelegaladvocate.com
InflaRx N.V. (IFRX) Surges 7.5% as Shares Test Key Resistance LevelWave Equality - The Legal Advocate
InflaRx (IFRX) Surges 6.5% as Stock Tests Key ResistancePut Call Ratio - dars.gov.et
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):